AI Article Synopsis

  • The Personality Assessment Inventory (PAI) is widely used in legal contexts for evaluating personality and mental health issues in criminal and civil cases.
  • The review of U.S. case law shows that the PAI is commonly applied in preadjudication mental health evaluations and social security disability cases, providing insight into examinee behavior and psychopathology.
  • While challenges to the PAI's admissibility are rare, the effectiveness of its results depends on the specific legal context and the characteristics of the individuals being assessed.

Article Abstract

The (PAI), a popular measure of personality, psychopathology, and interpersonal functioning, has demonstrated utility to address various psycholegal questions. This case law review examines a large sample of randomly selected published U.S. case law decisions to ascertain how the PAI has been applied and considered by legal decision makers. The review indicates the instrument is popular in criminal and civil legal settings, particularly in preadjudication forensic mental health evaluations (e.g., competency to proceed) and cases considering social security disability benefits. Forensic evaluators and legal actors primarily consider the results of the PAI as indicators of examinee impression management, psychopathology, and interpersonal functioning, although this varied by psycholegal context. The admissibility of the instrument was rarely challenged, although some challenges to the forensic evaluator's interpretation and conclusions emerged. Despite the PAI's popularity, the utility of the instrument is determined by specific, empirically supported, contexts. As such, forensic evaluators must consider how the PAI may inform decision making given examinee characteristics and the psycholegal question.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00223891.2021.1975723DOI Listing

Publication Analysis

Top Keywords

case law
12
psychopathology interpersonal
8
interpersonal functioning
8
forensic evaluators
8
consider pai
8
personality assessment
4
assessment inventory
4
inventory case
4
law survey
4
survey examination
4

Similar Publications

In Ukraine, patients and their family members face numerous barriers to health care services. In response, they use coping strategies, that are manifold and complex activities aimed at overcoming these barriers, the financial burden of the treatment, and the poor quality of health care services. These activities include formal and informal practices.

View Article and Find Full Text PDF

Background: Dignity therapy is a brief, structured psychotherapeutic intervention originally designed to help last-stage cancer patients maintain their dignity. It consists of a semi-structured interview encouraging patients to talk about their lives. The recorded session are transcribed and edited, after which the patient has the opportunity to make further changes to the final document.

View Article and Find Full Text PDF

Background: Dengue fever (DF) is a mosquito-borne viral infection that has recently become a burden worldwide, particularly in low-income countries, such as Yemen. There have been no epidemiological studies on DF in recent years in Yemen. Therefore, based on secondary data, this study aimed to shed light on the epidemiology of DF in Yemen between 2020 and 2024.

View Article and Find Full Text PDF

Pediatric cerebellar tumor survivors may present with spontaneous language impairments following treatment, but the nature of these impairments is still largely unclear. A recent study by Svaldi et al. (Cerebellum.

View Article and Find Full Text PDF

Accelerating biosimilar market access: the case for allowing earlier standing.

J Law Biosci

January 2025

Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, 1620 Tremont St. Suite 3030, Boston, MA 02120, USA.

Biosimilars, which are affordable alternatives to biologic medicines, face delays in market entry due to the current patent litigation framework under the Biologic Price Competition and Innovation Act. Currently, biosimilar manufacturers can only initiate patent litigation to attempt to clear weak and invalid patents after submitting their Biologic License Application to the Food and Drug Administration (FDA), which happens after completing extensive, and costly clinical trials. By contrast, generic drug manufacturers can start litigation earlier due to shorter development times and less stringent clinical requirements, allowing them to launch immediately after the primary patent expires.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!